Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Is There Any Good Reason Left to Delay Hepatitis C Treatment?

Physicians increasingly argue that the best choice is to get rid of hepatitis C right away. But your insurance company may not agree. How risky is it to wait for treatment?

Published
17 April 2015
From
Poz
Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

Published
09 April 2015
From
The Street
Abstracts Have Been Posted: International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

Abstracts for The International Liver Congress™ 2015 for the 50th annual meeting of the European Association for the Study of the Liver (EASL) are now available.

Published
09 April 2015
From
HCV New Drugs Research
WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine

The World Health Organization has issued a guidance document on the design of bioequivalence studies for a leading hepatitis C medicine. Generic drug companies seeking prequalification by the WHO need to demonstrate that their generic version is equivalent to the originator drug.

Published
08 April 2015
From
Intellectual Property Watch
Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir`

Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week’s time. The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries.

Published
31 March 2015
From
Cipla press release
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C

Primarily due to HCV, Japan has one of the highest rates of liver cancer of any industrialized country. Of the more than one million people chronically infected with HCV, 20-30 percent have the genotype 2 strain of the virus.

Published
31 March 2015
From
Gilead press release
World first trials for hepatitis C wonder drug in Sydney's maximum security jails

Two of NSW's maximum security jails are the location for a world-first trial of a new wonder drug that could stop the spread of the blood-borne disease hepatitis C through the prison populations.

Published
30 March 2015
From
Sydney Morning Herald
KEI Europe asks Romanian government to issue compulsory licences on hepatitis C medicines

For a country with a gross national income (GNI) per capita of $9,060, roughly one-quarter of the overall GNI per capita across the EU, the medicines are simply too costly to be within reach of patients in need, and put strains on the government's ability to provide reimbursements.

Published
23 March 2015
From
Knowledge Ecology International
Indian generic companies should reject Gilead’s controversial hepatitis C ‘Anti-Diversion’ programme

Ahead of a meeting in Jaipur, India next week between US pharmaceutical company Gilead Sciences and several Indian companies which have entered into an agreement with Gilead to produce hepatitis C drugs, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the generic companies to reject a highly-controversial programme that could compromise people’s treatment and confidentiality.

Published
19 March 2015
From
MSF
Gilead to require proof of citizenship to buy Sovaldi in poor countries

Médecins Sans Frontières/Doctors Without Borders (MSF) is urging Gilead to drop some of the provisions. If Gilead won't, MSF suggests that generic drugmakers ignore some of the requirements, like demanding that patients provide proof of citizenship to fill a prescription.

Published
19 March 2015
From
Fierce Pharma
← First12345...55Next →

Filter by country